European Commission offers hope for misunderstood intellectual disability and autism condition, FXS

The European Commission has granted Orphan Medicinal Product designation for zatolmilast an investigational treatment for Fragile X syndrome (FXS), a leading cause of inherited intellectual disability and autism.